Samidorphan

Cat. No.:	HY-123689
CAS No.:	852626-89-2
Molecular Formula:	$C_{21}H_{26}N_2O_4$
Molecular Weight:	370.44
Target:	Opioid Receptor; Opioid Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‑opioid, κ‑opioid, and δ‑opioid receptors. Samidorphan acts as an antagonist at μ‑opioid receptors and acts as a partial agonist at k-opioid and δ‑opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo[1].

REFERENCES

[1]. McElroy SL, et al. A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. Int J Eat Disord. 2013 Apr;46(3):239-45.

[2]. Mark S. Todtenkopf, et al. Buprenorphine in Combination with Samidorphan (ALKS 33) Results in Antidepressive-Like Effects in Two Distinct Rat Models. Eur Neuropsychopharmacol. 2014;24aSuppl 2):S366.

[3]. Rehan ST, et al. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. Ann Med Surg (Lond). 2022 Jun 30;79:104115.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA